Professional heparin API manufacturer with vertical industry integration

Global supplier of chondroitin sulfate (pharmaceutical grade and dietary supplement grade)

For over 20 years, Dongcheng has been deeply involved in the development of raw material medicine business and has become a vertically integrated professional heparin API manufacturer, global supplier of pharmaceutical grade and dietary supplement grade chondroitin sulfate, and one of the domestic biochemical raw material medicine production bases.

The heparin industry has rich production experience and strong production capacity. Dongcheng Pharmaceutical continuously strengthens the improvement of the heparin industry chain and has a vertically integrated industrial structure, ensuring product quality and traceability.

The company has an excellent background in qualification certification: domestic heparin sodium suppliers have passed the MFDS GMP audit of the South Korean Food and Drug Administration, passed the on-site inspection of PMDA GMP in Japan, and have GMP certificates issued by BGV in Hamburg, Germany and CFDA in China, as well as CEP certificates issued by EDQM in Europe; At the same time, the company assisted in the revision of standards for heparin sodium raw materials in the Chinese Pharmacopoeia (2010/2015 edition), European Pharmacopoeia, and United States Pharmacopoeia; The company participated in the heparin sodium expert group meeting held at USP headquarters in the United States as a supplier of heparin sodium raw materials.

As a domestic producer of chondroitin sulfate, the company currently has strong capabilities in research and development, quality, and sales. In 2016, the company acquired Zhongtai Biological Products Co., Ltd., further consolidating its position in the global chondroitin industry. In terms of qualification certification, the company is a chondroitin chondroitin producer certified by USP-DSIVP in the United States in China; Obtained CEP certificate issued by the EU EDQM, GMP certificate issued by BGV in Hamburg, Germany, MFDS in South Korea, ANVISA in Brazil, and CFDA in China. Given the company's technical authority in the domestic biochemical industry, it was invited to participate in the formulation of the quality standards for chondroitin sulfate sodium products in the Chinese Pharmacopoeia (2010/2015 edition).

The company has a well-established global sales network, with over 90% of its active pharmaceutical ingredients exported and sold in more than 40 countries and regions worldwide. Its partnerships with top pharmaceutical companies continue to grow steadily, and it has established close cooperation with internationally renowned dietary supplement manufacturers; And establish good cooperative relationships with well-known domestic pharmaceutical companies.

Based on the advantages of heparin raw materials, extend and expand to downstream formulations

Enhance the core competitiveness of the anticoagulant segmented market

Build well-known domestic and international brands of formulations

        In 2013, the company's board of directors proposed a development strategy that combines endogenous growth and outward expansion. Based on inheriting the advantages of existing heparin raw materials, the company expanded into new businesses in the formulation industry. In just nine months, Dongcheng Biopharmaceutical Industrial Park, as a platform for the development of formulation business, has emerged, laying a solid foundation for the enhancement of the company's core competitiveness.

The company has a rich pipeline of formulation products, with production lines for various dosage forms such as powder injections, tablets, capsules, granules, and drop pills. The products cover multiple therapeutic fields such as anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti infection. The company is based on the advantages of heparin raw materials and extends to downstream formulations. Currently, it has reserved multiple varieties of low molecular weight heparin formulations, laying the foundation for continuously building a well-known brand in the field of anticoagulation.

Fast track to enter the Chinese market

Experienced partners

Since 2014, Dongcheng Pharmaceutical has entered the high-tech barrier and high growth nuclear medicine industry with a high starting point. Dongcheng Nuclear Medicine has successively acquired Chengdu Yunke Pharmaceutical, Shanghai Yitai Pharmaceutical, and GMS (China), completing the company's full industry chain layout from diagnostic nuclear medicine to therapeutic nuclear medicine. In 2017, Dongcheng Pharmaceutical acquired 100% equity of Nanjing Andike Positron Research and Development Co., Ltd., further establishing the company's leading position in the field of nuclear medicine in China and becoming an enterprise that can provide comprehensive nuclear medicine solutions in the Chinese market.

As one of the leading nuclear medical enterprises in China, the company has established a leading domestic network for the production and distribution of radioactive drugs; The products on sale have achieved full coverage of "screening diagnosis treatment"; Multiple innovative varieties under research are in the preclinical and clinical trial stages. The company has initially formed five major platforms: nuclide supply platform, drug incubation platform, transformation service platform, production and distribution platform, and diagnosis and treatment marketing platform. It has basically completed the layout of the entire nuclear medical industry chain from raw material supply, research and development, clinical transformation, production, and sales, and has built a complete Dongcheng Pharmaceutical nuclear medical ecosystem.